TY - JOUR
AU - 
AB - Inhibition of the autocrine IL-6–JAK2– STAT3–calprotectin axis as targeted − + therapy for HR /HER2 breast cancers 1,8 2,3,8 1 1 Ruth Rodriguez-Barrueco, Jiyang Yu, Laura P. Saucedo-Cuevas, Mireia Olivan, 1 4 4 4 1 David Llobet-Navas, Preeti Putcha, Veronica Castro, Eva M. Murga-Penas, Ana Collazo-Lorduy, 1 2,3 1 5 Mireia Castillo-Martin, Mariano Alvarez, Carlos Cordon-Cardo, Kevin Kalinsky, 4,5 2,3,6,7 1 Matthew Maurer, Andrea Califano, and Jose M. Silva 1 2 Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; Department of Systems Biology, Center for Computational Biology and Bioinformatics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA; Institute for Cancer Genetics, Department of Pathology, Irving Cancer Research Center, Columbia University, New York, New York 10032, USA; Department of Medicine, Columbia University Medical Center, 6 7 New York, New York 10032, USA; Department of Biomedical Informatics, Department of Biochemistry and Molecular Biophysics, Institute for Cancer Genetics, Columbia University, New York, New York 10032 HER2-positive (HER2 ) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory − + network analysis, we identified 
TI - Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR<sup>−</sup>/HER2<sup>+</sup>breast cancers
JF - Genes & Development
DO - 10.1101/gad.262642.115
DA - 2015-07-30
UR - https://www.deepdyve.com/lp/unpaywall/inhibition-of-the-autocrine-il-6-jak2-stat3-calprotectin-axis-as-0TFitkmt5f
DP - DeepDyve
ER -